Suzdak Peter David 4
4 · REXAHN PHARMACEUTICALS, INC. · Filed Mar 2, 2018
Insider Transaction Report
Form 4
Suzdak Peter David
Chief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2018-02-28+6,250→ 18,750 total→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2018-02-28+6,250→ 22,250 total
Footnotes (2)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
- [F2]On January 20, 2017, the reporting person was granted 25,000 RSUs, of which 6,250 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019.